Corcept Therapeutics (CORT) Operating Expenses (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Operating Expenses data on file, last reported at $214.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 39.47% year-over-year to $214.5 million; the trailing twelve-month figure through Mar 2026 stood at $777.3 million (up 35.28% YoY), and the FY2025 full-year result was $716.6 million, up 33.18% from the prior year.
• Operating Expenses advanced to $214.5 million in Q1 2026, from $197.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $214.5 million in Q1 2026 to a low of $66.9 million in Q1 2022.
• A 5-year average of $125.5 million and a median of $117.3 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses gained 11.91% in 2022 and surged 50.99% in 2024, its largest moves.
• Tracing CORT's Operating Expenses over 5 years: stood at $80.6 million in 2022, then advanced by 28.77% to $103.7 million in 2023, then surged by 50.99% to $156.6 million in 2024, then climbed by 26.18% to $197.6 million in 2025, then gained by 8.53% to $214.5 million in 2026.
• Business Quant data shows CORT's Operating Expenses at $214.5 million in Q1 2026, $197.6 million in Q4 2025, and $197.4 million in Q3 2025.